**Author Listing - Lead/ Submitting Author (we will be communicating with this individual): Name, Institution, City and State where the work was done. Co-authors will be added in a separate section.**
Paolo Milani, Department of Molecular Medicine, University of Pavia, Pavia, Amyloidosis Research and Treatment Center, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy

**Main Body of the Abstract**
The only approved treatment for ATTRwt cardiac amyloidosis is tafamidis; however, benefits on overall survival emerge after approximately 18 months. The selection of patients whose expected survival exceeds this time is left to individual physicians and is often based on age only. We searched baseline variables able to discriminate patients at risk of death within 18 months in our prospectively maintained database (NCT05444920). Cut-offs were identified by Receiver Operator Characteristics (ROC) analyses. We considered clinical, laboratory and instrumental features of 691 consecutive patients diagnosed between 2006 and 2021. Median follow-up was 43 months and 367 patients (53%) died. As a simple means to assess frailty, we used ECOG Performance Status (PS) and found that 18-month cumulative proportion surviving (CPS18) was 94% in patients scoring 0 or 1. Early death was predicted by NT-proBNP (cutoff 4200 ng/L, area under the ROC curve [AUC] 0.82, 95%CI 0.78-0.84, CPS18 below and above the cutoff 96% and 75%, respectively, P≤0.001), cTnI (cutoff 92 ng/L, AUC 0.76, 95%CI 0.72-0.79, CPS18 95% and 78%, respectively, P<0.001), and age (cutoff 80 years, AUC 0.69, 95%CI 0.64-0.71, CPS18 92% and 79%, respectively, P<0.001). Since no single factor showed satisfactory specificity for early death, we defined high-risk subjects those in whom all markers were unfavorable. In low- (N=654, 95%) and high-risk (N=37, 5%) patients, median survival was 53 and 15 months and CPS18 91% and 40%, respectively (P<0.001), Figure. This simple scoring system identifies patients at very high-risk of early death who are unlikely to benefit from slow-acting drugs.



Predictors of early mortality in patients with wild-type transthyretin cardiac amyloidosis PC73 (#450)

We invite you to attend the XIX International Symposium on Amyloidosis to be held in Rochester, MN.

This symposium is organized as a hybrid meeting (with the focus on in-person) held from Sunday, May 26 through Thursday, May 30, 2024.

Together with the ISA Board and members of Mayo Clinic, a very attractive scientific hybrid program is being planned. The program will cover a variety of types of systemic amyloidosis: ATTR (hereditary and wild-type), AL (light-chain), AA and less frequent forms. There will be key lectures, specific symposia including those company sponsored, oral presentations and poster sessions of accepted abstracts.

COURSE DESCRIPTION
This program will provide a comprehensive review of state-of-the-art education in systemic amyloidosis: basic science, pathophysiology, diagnosis, current and emerging treatments. Scientific presentations will include competitive oral and poster abstracts. The rapid evolution of scientific discovery and expanding treatment options has created tremendous interest in the field and this meeting will fill and important gap in educating scientists and clinicians.